Date: 2015-05-11
Type of information: R&D agreement
Compound: programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells
Company: Astellas (Japan) Potenza Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On April 22, 2015, Astellas Pharma and Potenza Therapeutics, a biotechnology company developing a portfolio of immuno-oncology programs, announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration period. Under the terms of the collaboration agreement, Potenza will lead drug discovery activities and deliver development candidates to Astellas. Astellas will be responsible for clinical development activities and commercialization. Specific financial terms will not be disclosed, but include an equity investment, option fee, research funding, and potential future acquisition and milestone payments. Previously, Potenza closed a Series A equity financing of $38 million in December 2014 which was led by founding investor MPM Capital, with InterWest Partners and Astellas Venture Management LLC participating.
Financial terms:
Latest news:
